Tudor Investment Corp ET AL Makes New $351,000 Investment in Nurix Therapeutics, Inc. $NRIX

Tudor Investment Corp ET AL acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm acquired 37,943 shares of the company’s stock, valued at approximately $351,000.

Other hedge funds have also recently modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Nurix Therapeutics by 11.9% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,557,479 shares of the company’s stock valued at $14,391,000 after acquiring an additional 165,841 shares in the last quarter. Affinity Asset Advisors LLC boosted its position in Nurix Therapeutics by 19.4% in the second quarter. Affinity Asset Advisors LLC now owns 967,620 shares of the company’s stock worth $11,021,000 after purchasing an additional 156,951 shares during the last quarter. Bollard Group LLC purchased a new position in Nurix Therapeutics in the second quarter worth $1,398,000. Handelsbanken Fonder AB grew its stake in Nurix Therapeutics by 85.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 520,000 shares of the company’s stock valued at $4,805,000 after purchasing an additional 240,000 shares during the period. Finally, Nikko Asset Management Americas Inc. grew its stake in Nurix Therapeutics by 83.8% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,389,274 shares of the company’s stock valued at $15,796,000 after purchasing an additional 633,304 shares during the period.

Nurix Therapeutics Stock Down 0.1%

NRIX opened at $15.48 on Thursday. The firm has a 50-day moving average price of $16.03 and a 200-day moving average price of $14.97. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $22.50. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -5.09 and a beta of 1.96.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Wednesday, January 28th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.02. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. The company had revenue of $13.58 million for the quarter, compared to analysts’ expectations of $13.41 million. On average, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NRIX has been the topic of a number of recent analyst reports. Stifel Nicolaus lifted their target price on Nurix Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Needham & Company LLC restated a “buy” rating and set a $26.00 price target on shares of Nurix Therapeutics in a research report on Thursday, January 29th. Mizuho raised their price objective on shares of Nurix Therapeutics from $24.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Royal Bank Of Canada lifted their price objective on shares of Nurix Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Finally, Piper Sandler boosted their target price on shares of Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $30.54.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,661 shares of Nurix Therapeutics stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $60,772.60. Following the completion of the transaction, the chief financial officer owned 45,427 shares of the company’s stock, valued at $754,088.20. The trade was a 7.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Gwenn Hansen sold 4,895 shares of the company’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $81,257.00. Following the sale, the insider owned 83,672 shares in the company, valued at approximately $1,388,955.20. This represents a 5.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.40% of the stock is currently owned by insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.